- Home
- UAMY vs GLUE Comparison
UAMY vs GLUE Comparison
Compare UAMY & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- GLUE
- Stock Information
- Founded
- UAMY 1968
- GLUE 2019
- Country
- UAMY United States
- GLUE United States
- Employees
- UAMY N/A
- GLUE N/A
- Industry
- UAMY Metal Fabrications
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- GLUE Health Care
- Exchange
- UAMY Nasdaq
- GLUE Nasdaq
- Market Cap
- UAMY 316.8M
- GLUE 308.8M
- IPO Year
- UAMY N/A
- GLUE 2021
- Fundamental
- Price
- UAMY $5.90
- GLUE $13.57
- Analyst Decision
- UAMY Strong Buy
- GLUE Buy
- Analyst Count
- UAMY 6
- GLUE 2
- Target Price
- UAMY $4.75
- GLUE $15.00
- AVG Volume (30 Days)
- UAMY 14.5M
- GLUE 1.1M
- Earning Date
- UAMY 11-12-2025
- GLUE 11-06-2025
- Dividend Yield
- UAMY N/A
- GLUE N/A
- EPS Growth
- UAMY N/A
- GLUE N/A
- EPS
- UAMY N/A
- GLUE 0.25
- Revenue
- UAMY $31,857,819.00
- GLUE $181,538,000.00
- Revenue This Year
- UAMY $216.76
- GLUE $66.94
- Revenue Next Year
- UAMY $135.94
- GLUE N/A
- P/E Ratio
- UAMY N/A
- GLUE $54.27
- Revenue Growth
- UAMY 177.97
- GLUE 1112.27
- 52 Week Low
- UAMY $0.67
- GLUE $3.50
- 52 Week High
- UAMY $19.71
- GLUE $14.62
- Technical
- Relative Strength Index (RSI)
- UAMY 37.67
- GLUE 60.56
- Support Level
- UAMY $6.57
- GLUE $12.94
- Resistance Level
- UAMY $7.46
- GLUE $14.62
- Average True Range (ATR)
- UAMY 0.91
- GLUE 1.03
- MACD
- UAMY -0.20
- GLUE -0.13
- Stochastic Oscillator
- UAMY 1.97
- GLUE 66.06
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.